Following treatment with ATO, myeloma cell lines with varying p53 status, all showed upregulation of DR4 and DR5 and synergy with TRAIL (Akay and Gazitt, 2003; Liu et al, 2003). Here, TNFRSF10B is linked to plasma cell myeloma.